Jagsonpal Pharma sets May 4, 2026 as Record Date for ₹40 Cr Share Buyback
Jagsonpal Pharmaceuticals Limited has fixed May 04, 2026, as the Record Date for its share buyback program. The company plans to buy back up to 16,00,000 equity shares at ₹250 per share, totaling ₹40 crores.
A buyback announcement can positively influence shareholder value by reducing the number of outstanding shares and potentially increasing earnings per share. The record date is a crucial step in the execution of this plan.
The announcement is a procedural intimation regarding the record date for a previously announced buyback. It does not contain new financial performance data or significant operational changes that would alter the company's outlook.
Jagsonpal Pharmaceuticals Limited has announced that its Buyback Committee, constituted by the Board of Directors, has fixed Monday, May 04, 2026, as the Record Date. This date is for determining the entitlement and the names of equity shareholders eligible to participate in the proposed buyback of up to 16,00,000 fully paid-up equity shares.
The buyback will be conducted at a price of ₹250 per share, for an aggregate amount not exceeding ₹40 crores. This intimation is made pursuant to Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Regulation 9(i) of SEBI (Buy-back of Securities) Regulations, 2018.
What to do with a filing like this
Jagsonpal Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under buyback announcement. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jagsonpal Pharmaceuticals Limited. Read the original for the full detail.